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Rationale: Genomic loci are associated with FEV1 or the ratio of FEV1
to FVC in population samples, but their association with chronic
obstructive pulmonary disease (COPD) has not yet been proven,
nor have their combined effects on lung function and COPD been
studied.
Objectives: To test association with COPD of variants at five loci
(TNS1, GSTCD, HTR4, AGER, and THSD4) and to evaluate joint effects
on lung function and COPD of these single-nucleotide polymor-
phisms (SNPs), and variants at the previously reported locus near
HHIP.
Methods: By sampling from 12 population-based studies (n ¼
31,422), we obtained genotype data on 3,284 COPD case subjects
and 17,538 control subjects for sentinel SNPs in TNS1, GSTCD, HTR4,
AGER, and THSD4. In 24,648 individuals (including 2,890 COPD case
subjects and 13,862 control subjects),we additionally obtainedgen-
otypes for rs12504628 near HHIP. Each allele associated with lung
function decline at these six SNPs contributed to a risk score. We
studied the association of the risk score to lung function and COPD.
Measurements and Main Results: Association with COPD was signifi-
cant for three loci (TNS1, GSTCD, and HTR4) and the previously
reported HHIP locus, and suggestive and directionally consistent
for AGER and TSHD4. Compared with the baseline group (7 risk
alleles), carrying 10–12 risk alleles was associated with a reduction
in FEV1 (b¼ –72.21ml, P¼ 3.903 1024) and FEV1/FVC (b¼ –1.53%,
P¼6.3531026), andwithCOPD(odds ratio¼1.63,P¼1.4631025).
Conclusions: Variants in TNS1, GSTCD, and HTR4 are associated with
COPD.Our highest risk score categorywas associatedwith a 1.6-fold
higher COPD risk than the population average score.
Keywords: FEV1; FVC; genome-wide association study; modeling risk
Chronic obstructive pulmonary disease (COPD), characterized
by airflow limitation that is not fully reversible, affects approx-
imately 210 million people worldwide (1) and is among the
leading causes of death in developed and developing countries
(2, 3). Tobacco smoking is a potent cause of COPD, but not all
smokers develop COPD and genetic determinants are also im-
portant (4). Identification of the genetic determinants of COPD
could provide insight into molecular pathways that may be ame-
nable to improved preventive and treatment strategies. A fur-
ther potential utility of newly identified genetic associations is
to predict disease risk. Current evidence available from com-
mon complex diseases where family history may be used, such
as type 2 diabetes, suggests that tens of genetic variants with
individually modest effects may provide similar but not neces-
sarily substantially improved disease risk prediction over exist-
ing scores that incorporate family history (5, 6)
Genetic variants in SERPINA1 that cause a1-antitrypsin de-
ficiency have long been known to affect COPD risk. Although
there had been limited success in identifying additional suscep-
tibility loci for COPD until 2009 (7), more recent genome-wide
association (GWA) studies have shown associations between
genetic loci and lung function measures that underpin the di-
agnosis of COPD (8–10). Two of these studies have investigated
genome-wide association with lung function in large sample
sizes (.20,000 subjects), focusing exclusively on quantitative
lung function measures (8, 9). Since the advent of dense
GWA genotyping platforms, the only loci convincingly associ-
ated with COPD have been HHIP (10, 11), which to date
remains the strongest signal, CHRNA3/5 (11), and FAM13A
(12).
We hypothesized that genetic variants associated with FEV1
and FEV1/FVC would be associated with COPD. In a study of
20,288 individuals with GWA data and follow-up of top signals
in a further 54,276 individuals (SpiroMeta Consortium), we pre-
viously identified five novel loci showing association (P , 5 3
1028) with FEV1 or FEV1/FVC: in TNS1 at 2q35, in GSTCD at
4q24, in HTR4 at 5q33, in AGER at 6p21, and in THSD4 at
15q23 (9).
In this article, based on the five loci reported by the SpiroMeta
Consortium (9), we further investigate the clinical relevance
of these loci. First, we test association of the sentinel single-
nucleotide polymorphism (SNP) at each locus with COPD. Sec-
ond, we investigate the combined effect of the risk alleles at all
five novel loci described previously (TNS1, GSTCD, HTR4,
AGER, and THSD4) and the previous association at 4q31 (near
HHIP) (10) on lung function and COPD risk.
Some of the results of these studies have been previously
reported in the form of abstracts (13, 14).
METHODS
Study 1: Single SNP Analysis of TNS1, GSTCD, HTR4, AGER,
THSD4 with COPD
Populations, phenotyping, and genotyping. Figure 1 shows the study pop-
ulations and loci included in the study design. The study population
consisted of 31,422 individuals over the age of 40 years from 12
population-based studies. These studies included the European Pro-
spective Investigation into Cancer and Nutrition obese cases cohort
(EPIC-obese case subjects) and population cohort (EPIC population-
based), Generation Scotland: Scottish Family Health Study (GS:
SFHS), Cooperative Health Research in the Region of Augsburg
(KORA F4), Adult-onset Asthma and Nitric Oxide (ADONIX) Study,
Busselton Health Study (BHS), British Regional Heart Study (BRHS),
British Women’s Heart and Health Study (BWHHS), Gedling Study
(Gedling), Hertfordshire Cohort Study (HCS), Finnish Health 2000
Survey (Health 2000), Nottingham Smokers Study (Nottingham Smok-
ers), and Medical Research Council National Survey of Health and
Development (NSHD, or British 1946 Birth Cohort).
FEV1 and the ratio of FEV1 to FVC were measured in each study,
using the spirometry methods detailed in the online supplement. The
percent predicted FEV1 was calculated according to previously described
prediction equations (15, 16). Individuals with percent predicted FEV1
less than 80% and FEV1/FVC less than 0.7 (Global Initiative for Chronic
Obstructive Lung Disease [GOLD] stages 2–4) were classified as COPD
case subjects (17). Individuals with FEV1 greater than 80% predicted
and FEV1/FVC greater than 0.7 were classified as control subjects. To
minimize potential misclassification of COPD case subjects and control
subjects, individuals not falling in either category (GOLD stage 1) were
excluded from the analyses of COPD risk. We also excluded related
individuals from the case–control analyses.
Genotyping was undertaken for a sentinel SNP at each of the follow-
ing loci: TNS1 (rs2571445), GSTCD (rs10516526), HTR4 (rs3995090),
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Genome-wide association studies have reported novel loci
for lung function, but the association of these loci with
chronic obstructive pulmonary disease (COPD) has not yet
been tested, and their effects in combination have not yet
been documented.
What This Study Adds to the Field
We show associations between COPD and polymorphisms
in HTR4, GSTCD, and TNS1. Using a six-SNP (single-
nucleotide polymorphism) risk score, incorporating var-
iants in HTR4, GSTCD, TNS1, AGER, THSD4, and near
HHIP, the highest risk category (z5% of Europeans) is
associated with a 1.6- fold risk of COPD compared with
a common baseline group.
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AGER (rs2070600), and THSD4 (rs12899618). Standard quality con-
trol approaches were used. To incorporate the previously reported
locus near HHIP into the analyses, rs12504628 was genotyped in stud-
ies that employed KASPar genotyping (KBioscience, Hoddesdon,
Herts, UK) and available in silico data for rs12504628 were used for
EPIC, Health 2000, and a subset of BHS (footnote y in Table 1).
Statistical analysis. Each SNP genotype was coded 0, 1, or 2, corre-
sponding to the number of copies of the coded allele. The effect esti-
mates were oriented to the forward strand of the National Center for
Biotechnology Information (NCBI) build 36 reference sequence of
the human genome, using the alphabetically higher allele as the coded
allele. For each of the five SNPs reported by the SpiroMeta Consortium
(9), logistic regression was used within each study population to test
association of the SNP with COPD. Adjustments for additional cova-
riates were not used for this analysis given that the percent predicted
FEV1 (used to define COPD) includes adjustments for age, sex, and
height (18). We defined Bonferroni-corrected statistical significance
as P less than 0.01, to account for the testing of the five independent
SNPs. After quality checks of the study population level data, pooled
effect size estimates and their standard errors were computed across
all studies, using an inverse variance weighting. Although previously
shown to be associated with COPD and therefore not the focus of our
analysis, for completeness we present the associations with rs12504628
(near HHIP).
Study 2: Joint Effects of TNS1, GSTCD, HHIP, HTR4, AGER, and
THSD4 Loci on Lung Function and COPD
Populations. The studies and loci included in study 2 are shown in
Figure 1. We included the subset of studies that were genotyped for
all six SNPs and that were not in the set of GWA data that led to the
discovery of these loci (9). This restriction was to avoid cumulative
biases resulting from individual SNP estimates of association that tend
to be biased away from the null in “hits” from genome-wide discovery
sets (winner’s curse bias) (19). The phenotyping and genotyping of
these studies were undertaken as described for study 1.
Statistical analysis: derivation of the risk score. To derive an un-
weighted risk allele score theoretically ranging from 0 to 12, each allele pre-
viously associated with reduced FEV1 or FEV1/FVC (9) contributed one
to the risk score. The risk alleles for the six loci were as follows: A for
rs2571445 (TNS1), A for rs10516526 (GSTCD), T for rs12504628 (HHIP),
A for rs3995090 (HTR4), C for rs2070600 (AGER), and A for rs12899618
(THSD4). We categorized the risk scores into five groups; 0–4, 5–6, 7
(median number of risk alleles, baseline group), 8–9, and 10–12 risk alleles.
Statistical analysis: testing association between the risk score and lung
function. We performed linear regressions of FEV1 and FEV1/FVC
onto age, age squared, sex, and height to obtain residual phenotypes.
Linear regressions were undertaken with each residual phenotype as
the outcome variable, and an intercept and four indicator variables (for
the four nonbaseline risk allele groups) as the explanatory variables to
test for association. After quality checks of study level data, we com-
puted pooled estimates using an inverse variance weighting.
Statistical analysis: testing association between the risk score and
COPD. Individuals were classified as COPD case subjects (GOLD stages
2–4) or control subjects on the basis of the criteria described previously
for study 1. To test the association of the unweighted risk allele score
with COPD we used logistic regression with COPD as the outcome, an
intercept, and the four indicator variables. Study level estimates were
pooled after quality checks using an inverse variance weighting.
RESULTS
Study 1: Single SNP Analysis of TNS1, GSTCD, HTR4, AGER,
and THSD4 with COPD
The characteristics of the study participants are shown in Table
1. For the individual SNP associations with COPD a total of
3,284 individuals were classified as COPD case subjects (percent
predicted FEV1 , 80% and FEV1/FVC , 0.7) and 17,538 indi-
viduals as control subjects (FEV1 . 80% predicted and FEV1/
FVC . 0.7). Of the variants at the five loci shown to be asso-
ciated with lung function (9), variants at three loci showed sig-
nificant association with COPD: rs2571445 in TNS1 (odds ratio
[OR] per A allele, 1.10; 95% confidence interval [CI], 1.03–1.16;
P ¼ 1.89 3 1023) (Figures 2 and 3), rs10516526 in GSTCD (OR
per A allele, 1.24; 95% CI, 1.10–1.40; P ¼ 3.75 3 1024) (Figures
2 and 3), and rs3995090 in HTR4 (OR per A allele, 1.12; 95%
Figure 1. Study design. Single-nucleotide poly-
morphisms (SNPs) genotyped at each of the loci
listed were rs2571445 (TNS1), rs10516526
(GSTCD), rs12504628 (near HHIP), rs3995090
(HTR4), rs2070600 (AGER), and rs12899618
(THSD4). Study 1 included all participating stud-
ies. Study 2 included the subset of studies that
were genotyped for all six SNPs and that were
not included in the discovery set of genome-
wide association study (GWAS) data that led
to the discovery of our five loci (9). Individuals
excluded from study 2 chronic obstructive pul-
monary disease (COPD) analyses were as fol-
lows: (1) individuals under the age of 40 years,
(2) individuals with stage 1 COPD (FEV1/FVC ,
0.7 and percent predicted FEV1. 80%), and (3)
individuals with FEV1/FVC greater than 0.7 but
percent predicted FEV1 less than 80%. Study
abbreviations are as follows: EPIC obese case
subjects (European Prospective Investigation in-
to Cancer and Nutrition-obese case subjects)
and EPIC population-based (European Prospec-
tive Investigation into Cancer and Nutrition co-
hort), GS:SFHS (Generation Scotland: Scottish
Family Health Study), KORA F4 (Cooperative
Health Research in the Region of Augsburg),
ADONIX (Adult-onset Asthma and Nitric Oxide), BHS (Busselton Health Study), BRHS (British Regional Heart Study), BWHHS (British Women’s
Heart and Health Study), Gedling (Gedling Study), HCS (Hertfordshire Cohort Study), Health 2000 (Finnish Health 2000 Survey), Nottingham
Smokers (Nottingham Smokers Study), and NSHD (Medical Research Council National Survey of Health and Development, also known as the British
1946 Birth Cohort).
788 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 184 2011
TABLE 1. STUDY CHARACTERISTICS
Study Name Subset
No. in
Study 1
No. in
Study 2
Male (n);
Female (n)
Age: Mean
(SD) (yr)
FEV1: Mean
(SD) (L)
FEV1 Predicted:
Mean (SD) (L)
FVC: Mean
(SD) (L)
FEV1/FVC Ratio:
Mean (SD)
Never-
smokers
(n); Ever-
smokers (n)
COPD
Severity
(% of COPD
Case Subjects
in GOLD
Stage 3 or 4) Genotyping
Study 1 Single SNP Analysis: GWAS (Discovery) Stage
EPIC obese
case subjects
All 1,104 476; 628 59.1 (8.8) 2.35 (0.69) 2.91 (0.62) 2.84 (0.87) 0.82(0.17) 489; 615 Affymetrix
500K
Case
subjects
75 47; 28 60.64 (8.45) 1.82 (0.67) 3.09 (0.63) 3.01 (1.05) 0.61 (0.09) 22; 53 30.14
Control
subjects
599 252; 347 58.30 (8.76) 2.67 (0.62) 2.88 (0.61) 3.13 (0.79) 0.86 (0.07) 281; 318
EPIC
population-
based
All 2,336 1,100; 1,236 59.2 (9.0) 2.50 (0.72) 2.95 (0.62) 3.04 (0.90) 0.85 (0.16) 1,061; 1,275 Affymetrix
500K
Case
subjects
190 105; 85 62.31 (8.54) 1.81 (0.62) 2.95 (0.63) 3.00 (0.96) 0.60 (0.09) 72; 118 20.11
Control
subjects
1,442 677; 765 58.76 (8.81) 2.78 (0.64) 2.94 (0.62) 3.29 (0.82) 0.85 (0.08) 709; 733
Study 1 Single SNP Analysis: Follow-up (Nondiscovery) Stage
GS:SFHS All 5,474 2,254; 3,220 46.0 (14.3) 3.15 (0.87) 3.32 (0.75) 4.11 (1.03) 0.77 (0.10) 3,005; 2,469 TaqMan
Case
subjects
335 118; 217 58.4 (9.2) 1.89 (0.54) 2.89 (0.59) 3.32 (0.85) 0.58 (0.10) 123; 212 11.94
Control
subjects
2,567 1,053:1,514 53.2 (8.5) 3.12 (0.72) 3.11 (0.63) 3.99 (0.91) 0.78 (0.07) 1,457; 1,110
KORA F4 All 1,305 610; 695 51.6 (5.7) 3.32 (0.81) 3.29 (0.63) 4.28 (1.00) 0.78 (0.06) 499; 806 TaqMan
Case
subjects
59 30; 29 53.4 (6.0) 2.14 (0.66) 3.24 (0.64) 3.47 (0.96) 0.61 (0.06) 12; 47 10.17
Control
subjects
1,109 512; 597 51.5 (5.7) 3.45 (0.76) 3.28 (0.62) 4.36 (0.96) 0.79 (0.04) 456; 653
Study 1 Single SNP Analysis and Study 2 Joint Effects Analyses: Follow-up (Nondiscovery) Stage
ADONIX All 1,423 1,282 669; 754 49.1 (13.5) 3.34 (0.86) 3.23 (0.66) 4.24 (1.02) 0.79 (0.07) 798; 625 KASPar*
Case
subjects
46 41 27; 19 55.7 (9.3) 2.02 (0.57) 3.23 (0.66) 3.35 (0.87) 0.60 (0.07) 12; 34 13.04
Control
subjects
783 711 361; 422 61.4 (8.4) 3.23 (0.73) 3.23 (0.67) 4.08 (0.91) 0.79 (0.04) 448; 335
BHS All† 4,350 787 1,793; 2,557 50.1 (17.0) 3.02 (0.97) 3.18 (0.82) 3.89 (1.16) 0.77 (0.08) 2,459; 1,891 TaqMan
Case
subjects†
200 92 132; 68 66.9 (11.6) 1.60 (0.60) 2.85 (0.66) 2.73 (0.91) 0.58 (0.09) 67; 133 19.5
Control
subjects†
2,307 386 944; 1,363 57.9 (12.3) 2.87 (0.83) 2.93 (0.73) 3.66 (1.05) 0.78 (0.05) 1,387; 920
BRHS All 3,877 3,415 3,877; 0 68.7 (5.5) 2.57 (0.69) 3.03 (0.4) 3.37 (0.84) 0.77 (0.12) 1,125; 2,752 KASPar*
Case
subjects
641 572 641; 0 69.7 (5.4) 1.76 (0.51) 3 (0.4) 3.01 (0.8) 0.59 (0.09) 111; 530 28.39
Control
subjects
2,168 1,905 2,168; 0 68.3 (5.5) 2.96 (0.48) 3.03 (0.4) 3.65 (0.65) 0.82 (0.07) 760; 1,408
BWHHS All 3,644 3,319 0; 3,644 68.8 (5.5) 1.98 (0.52) 2.16 (0.31) 2.82 (0.76) 0.71 (0.09) 2,060; 1,584 KASPar*
Case
subjects
659 600 0; 659 69.8 (5.4) 1.36 (0.35) 2.14 (0.3) 2.32 (0.54) 0.59 (0.08) 253; 406 15.63
Control
subjects
1,808 1,653 0; 1,808 68.2 (5.4) 2.23 (0.41) 2.18 (0.3) 2.93 (0.56) 0.76 (0.05) 1,153; 655
Gedling All 1,263 1,188 632; 631 56.2 (12.3) 2.85 (0.85) 3.07 (0.69) 3.68 (1.02) 0.77 (0.07) 633; 630 KASPar*
Case
subjects
103 98 67; 36 66.2 (9.1) 1.73 (0.61) 2.88 (0.66) 2.82 (0.83) 0.61 (0.09) 21; 82 24.27
Control
subjects
840 789 417; 423 57.3 (9.8) 3 (0.73) 3.03 (0.65) 3.8 (0.9) 0.79 (0.04) 431; 409
HCS All 2,850 2,343 1,511; 1,339 66.1 (2.8) 2.44 (0.68) 2.80 (0.55) 3.42 (0.92) 0.72 (0.09) 1,319; 1,531 KASPar*
Case
subjects
536 441 308; 228 66.3 (2.8) 1.84 (0.55) 2.87 (0.56) 2.09 (0.85) 0.60 (0.09) 159; 377 15.1
Control
subjects
1,519 1,264 758; 761 66.0 (2.9) 2.67 (0.60) 2.75 (0.54) 3.51 (0.82) 0.76 (0.04) 837; 682
Health 2000 All 888 882 427; 456 50.2 (11.0) 3.32 (0.91) 3.14 (0.67) 4.19 (1.08) 0.79 (0.07)) 266; 617 Illumina
610K
Case
subjects
32 32 20; 12 60.91 (8.83) 1.78 (0.68) 3.05 (0.66) 3.05 (0.95) 0.58 (0.10) 5; 27 37.5
Control
subjects
580 580 256; 324 53.19 (8.31) 3.28 (0.77) 3.15 (0.67) 4.09 (0.97) 0.80 (0.05) 192; 388
(Continued )
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CI, 1.05–1.18; P ¼ 1.79 3 1024) (Figures 2 and 3). The asso-
ciations with COPD were in the direction expected, given
the reported direction of these allelic effects on lung function
(Figure 2) (9). The point estimates of the effects on COPD
for the sentinel SNPs in AGER (rs2070600) and in THSD4
(rs12899618) were of the magnitude and direction expected,
but did not reach statistical significance. Although it was not a
primary aim of our study to investigate the association between
COPD and the locus nearHHIP at 4q31 (an association reported
by several studies [10, 11, 20]), we were also able to test this in
a subset of our data (2,890 case subjects and 13,862 control sub-
jects) for which the rs12504628 genotype was available. We con-
firmed the association between the 4q31 locus and COPD: OR
per rs12504628 T allele, 1.19 (95% CI, 1.12–1.27) and P ¼ 4.55 3
TABLE 1. (CONTINUED)
Study Name Subset
No. in
Study 1
No. in
Study 2
Male (n);
Female (n)
Age: Mean
(SD) (yr)
FEV1: Mean
(SD) (L)
FEV1 Predicted:
Mean (SD) (L)
FVC: Mean
(SD) (L)
FEV1/FVC Ratio:
Mean (SD)
Never-
smokers
(n); Ever-
smokers (n)
COPD
Severity
(% of COPD
Case Subjects
in GOLD
Stage 3 or 4) Genotyping
Nottingham
Smokers
All 509 466 280; 229 59.5 (10.4) 2.00 (0.95) 2.98 (0.61) 3.02 (1.06) 0.64 (0.16) 0; 509 KASPar*
Case
subjects
242 227 145; 97 63.2 (9.5) 1.28 (0.57) 2.87 (0.59) 2.5 (0.87) 0.51 (0.12) 0; 242 64.46
Control
subjects
153 138 70; 83 54.8 (8.9) 2.89 (0.61) 3.08 (0.62) 3.69 (0.81) 0.79 (0.05) 0; 153
NSHD All 2,404 2,201 1,206; 1,198 53 (0) 2.80 (0.70) 3.20 (0.56) 3.51 (0.89) 0.80 (0.09) 1,003; 1,401 KASPar*
Case
subjects
166 149 102; 64 53 (0) 2.11 (0.58) 3.35 (0.54) 3.46 (0.89) 0.61 (0.08) 49; 117 15.06
Control
subjects
1,663 1,526 848; 815 53 (0) 3.03 (0.62) 3.20 (0.56) 3.69 (0.81) 0.83 (0.06) 765; 898
Total All 31,422 15,883
Case
subjects
3,284 2,252
Control
subjects
17,538 8,952
Definition of abbreviations: ADONIX ¼ Adult-onset Asthma and Nitric Oxide Study; BHS ¼ Busselton Health Study; BRHS ¼ British Regional Heart Study; BWHHS ¼ British Women’s Heart and
Health Study; COPD ¼ chronic obstructive pulmonary disease; EPIC ¼ European Prospective Investigation into Cancer and Nutrition; GOLD ¼ Global Initiative for Chronic Obstructive Lung Disease;
GS:SFHS ¼ Generation Scotland: Scottish Family Health Study; GWAS ¼ genome-wide association study; HCS ¼ Hertfordshire Cohort Study; KORA F4 ¼ Cooperative Health Research in the Region
of Augsburg; NSHD ¼ Medical Research Council National Survey of Health and Development.
* KASPar genotyping (KBiosciences, Hoddesdon, Herts, UK; http://www.kbioscience.co.uk/).
y The BHS had genotype data for HHIP only for a subset of individuals (n ¼ 1,168, 131 COPD case subjects and 565 control subjects); this is therefore the subset included in study 2.
Figure 2. Association of sentinel single-nucleotide poly-
morphisms (SNPs) at five novel lung function loci and
a previously reported HHIP SNP with chronic obstructive
pulmonary disease (COPD), and comparison with
reported associations with FEV1 and FEV1/FVC. Shown
are the results for COPD after testing for association in
3,284 COPD case subjects and 17,538 control subjects,
and a comparison with the associations with FEV1 and
FEV1/FVC in the combined discovery and follow-up data
reported by Repapi and colleagues (9). Boxes indicate the
point estimates of the effect sizes and whiskers the 95%
confidence intervals.
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1028. We tested for heterogeneity of effect sizes across the stud-
ies for each SNP; a chi-squared heterogeneity test was not statis-
tically significant (P . 0.10) for any of the six SNPs.
As expected, a much higher proportion were ever-smokers
among COPD case subjects (72%) than among control subjects
(49%). This raises the possibility that these variants could influ-
ence COPD risk via an effect on smoking behavior. Therefore we
explored whether the effects on COPD risk could be mediated
via smoking. First, we examined the effects of an additional pack-
years adjustment in smokers in a subset of our data with pack-
years available and obtained similar results to those without
adjustment for pack-years (see Figure E1 in the online sup-
plement). Second, we assessed the association between these
SNPs and two smoking behavior phenotypes in the Oxford-
GlaxoSmithKline (Ox-GSK) consortium data set (21). As
shown in Table E1, none of the SNPs showed even nominal
Figure 3. Forest plots of the
meta-analysis of association
tests with chronic obstructive
pulmonary disease (COPD)
for the six loci (TNS1, GSTCD,
HHIP, HTR4, AGER, and
THSD4). *rs12504628 (HHIP)
data were not available in GS:
SFHS or KORA F4. yKORA F4
failed to genotype rs3995090
(HTR4). ADONIX ¼ Adult-onset
Asthma and Nitric Oxide Study;
BHS ¼ Busselton Health Study;
BRHS ¼ British Regional Heart
Study; BWHHS ¼ British Wom-
en’s Heart and Health Study;
COPD ¼ chronic obstructive
pulmonary disease; EPIC ¼ Eu-
ropean Prospective Investiga-
tion into Cancer and Nutrition;
GS:SFHS ¼ Generation Scot-
land: Scottish Family Health
Study; HCS ¼ Hertfordshire Co-
hort Study; KORA F4 ¼ Coop-
erative Health Research in the
Region of Augsburg; NSHD ¼
Medical Research Council Na-
tional Survey of Health and
Development.
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association (P , 0.05) in 18,598 ever-smokers versus 15,041
never-smokers and none of the SNPs showed nominal associa-
tion with the number of cigarettes smoked per day (n ¼ 15,574).
This evidence strongly suggests that the effects of these variants
on lung function and COPD risk are not mediated via tobacco
addiction.
Study 2: Joint Effects of HHIP, TNS1, GSTCD, HTR4, AGER, and
THSD4 Loci on Lung Function and COPD
The characteristics of the study participants are shown in Table
1. In all, 15,883 individuals were included in the analyses of
FEV1 and FEV1/FVC (Table 1). A trend in lung function
(FEV1 and FEV1/FVC) was shown across risk allele categories
(Figure 4). Notably, compared with the baseline group of seven
risk alleles, carrying 10–12 risk alleles was associated with a re-
duction in FEV1 (coefficient –72.21 ml [95% CI, –112.12 to
–32.30 ml]; P ¼ 3.90 3 1024) and a reduction in FEV1/FVC
(coefficient –1.53% [95% CI, –2.20% to –0.87%]; P ¼ 6.35 3
1026). Approximately 5% of the study population carried 10–12
risk alleles and 28% of the study population carried seven risk
alleles. The magnitude of decline in FEV1 compared with the
baseline group is equivalent to the physiological average ageing
decline in lung function over approximately four years in a non-
smoking population (22).
To assess the joint effects of the risk alleles on COPD, data
from nondiscovery cohorts (Figure 1) with genotype data avail-
able on all six SNPs were used. This included 2,252 COPD case
subjects (percent predicted FEV1, 80% and FEV1/FVC, 0.7)
and 8,952 control subjects (FEV1 . 80% predicted and FEV1/
FVC. 0.7) as shown in Figure 1 and Table 1. Again, a clear trend
in COPD risk across the categories was observed (Figure 4).
Compared with a baseline of seven risk alleles, carrying 10 to 12
risk alleles was associated with an increased risk of COPD (OR,
1.63; 95% CI, 1.31–2.03; P ¼ 1.46 3 1025) (Figure 4).
DISCUSSION
In a study of the set of novel variants we reported to be associ-
ated with lung function (9), we show significant association with
COPD for three of the five loci—in HTR4, GSTCD, and
TNS1—emphasizing the clinical relevance of these loci to re-
spiratory disease. We also confirm the association between the
4q31 locus near HHIP and COPD, and show expected direction
and magnitude of effect (although nonsignificant) for the two
remaining of the five lung function loci studied. In addition, we
provide an estimate of the combined effect sizes of these loci on
lung function and COPD in studies independent of the data
used to discover these associations. We show that the highest
number of risk alleles (10–12 risk alleles, 5% of our population)
is associated with a 1.6-fold elevation of COPD risk, compared
with a common baseline group of individuals with 7 risk alleles
(28% of our population).
The loci associated with COPD may provide important
insights into the pathways underlying the development of
COPD. The sentinel SNP at the 4q24 locus (rs10516526) is
intronic in GSTCD, which encodes a glutathione S-transferase,
C-terminal domain–containing protein. This protein may be in-
volved in cellular detoxification, catalyzing conjugation of glu-
tathione to products of oxidative stress (23), and in regulating
the synthesis of prostaglandins and leukotrienes (23). GSTCD
also shows homology with chloride intracellular channels and
could therefore influence lung function via other molecular
pathways (9). A second locus associated with COPD was local-
ized to TNS1 at 2q35, where the sentinel variant was a nonsy-
nonymous coding SNP. Tensin-1 is an actin-binding protein
with SH2 (Src homology-2) domains, possibly involved in signal
transduction (24) and cell migration (25). At 5q33, the sentinel
variant was an intronic SNP (rs3995090) in HTR4 encoding the
5-hydroxytryptamine receptor-4 (HTR4), which is expressed in
neurons and airway epithelial type II cells, where it may
Figure 4. Association of risk scores with lung function and
chronic obstructive pulmonary disease (COPD). The risk
score theoretically ranges from 0 to 12 across the six loci
(TNS1, GSTCD, HHIP, HTR4, AGER, and THSD4). The risk
allele category was in each case compared with a baseline
of seven risk alleles. Boxes indicate the point estimates of
the effect sizes and whiskers the 95% confidence intervals.
kTo facilitate the plotting of the effect size estimates for
FEV1 and FEV1/FVC on the same axes, effect sizes are given
in terms of the proportion of a standard deviation of FEV1
and FEV1/FVC; we used a standard deviation of 752 ml for
FEV1 and 9.45% for FEV1/FVC (obtained as weighted aver-
ages across studies). **Proportion of individuals within
each risk score category.
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regulate cytokine responses (26). In contrast, the sentinel SNP
at 4q31 reported in our study (rs1250468) and that reported in
previous studies (rs13147758, r2 ¼ 0.97 with rs1250468) (10, 11),
lies in an intergenic region upstream of HHIP. The hedgehog
(Hh) gene family encodes signaling molecules involved in reg-
ulating lung morphogenesis (27), although this locus has been
previously associated with height (28), implicating a role in
skeletal growth and development.
Although we did not demonstrate a statistically significant as-
sociation between COPD and two loci, the estimated effects
were in the expected direction. These included a nonsynonymous
coding SNP (rs2070600) in AGER, within a gene-rich region of
the major histocompatibility complex (6q21), and an intronic
SNP (rs12899618) in TSHD4 (15q23). AGER is a strong candi-
date as it is highly expressed in the lung (29) and altered AGER
expression has been noted in COPD lung tissue (30) and in sub-
jects with idiopathic pulmonary fibrosis (31). Similarly the gene
product of THSD4 shows homology with the thrombospondin
family of extracellular calcium-binding proteins implicated in
wound healing, inflammation, and angiogenesis (32) and could
also be a good candidate for COPD development. Of the five
new loci (9) we examined, the loci showing association with
COPD in our data showed strongest association with FEV1
(HTR4, GSTCD, and TNS1), whereas the two loci that did not
show a significant association with COPD (AGER and THSD4)
showed association with FEV1/FVC, but without a strong associ-
ation with FEV1. A simpler explanation for these different find-
ings may be limited statistical power to detect the modest effects
of these common genetic variants on a binary outcome.
The effect sizes of the SNPs at the three loci associated with
COPD (HTR4, GSTCD, and TNS1) and the locus previously
reported (HHIP) are modest, in the range 1.10–1.24 per copy of
the risk allele at each locus. For the previously reported 4q31
locus near HHIP, we estimate an odds ratio of 1.19 (95% CI,
1.12–1.27) for COPD. Although larger effect sizes have been
described, for example, an odds ratio for COPD equivalent to
approximately 1.4 for the risk allele A at rs13118928 in the U.S.
National Emphysema Treatment Trial/Normative Ageing Study
and Bergen populations (11); the Rotterdam Study (20) and
Framingham Heart Study (10) described odds ratios of 1.25
and 1.10 for this allele. Although the differences in the effect
size estimates for the 4q31 locus could be attributable to differ-
ences in study characteristics, such as age, these differences
could be explained in part by winner’s curse bias (19), in which
the effect size is generally overestimated in the study that first
detects the association at the stringent levels of significance re-
quired in GWA studies. Additional evidence from independent
populations, such as that provided from our study, can be im-
portant in establishing effect size estimates that are likely to be
unaffected by such biases.
Most of the constituent studies did not measure postbroncho-
dilation spirometry, and therefore our analysis was limited to pre-
bronchodilation spirometry measures. In the Nottingham Smokers
Study, in which both pre- and postbronchodilation spirometry
were measured, the positive predictive value of prebronchodilation-
defined COPD for diagnosis of postbroncholidation-defined COPD
was 98% (Table E2). In all association tests reported in this ar-
ticle, we excluded individuals with GOLD stage 1 COPD from
both case subjects and control subjects. As has been shown previ-
ously (33), the use of prebroncholidation spirometry to diagnose
COPD when GOLD stage 1 COPD case subjects are included
would lead to substantial misclassification (e.g., in the Nottingham
Smokers Study the positive predictive value would decline to 89%;
Table E3). Demonstration of airflow obstruction with postbron-
chodilator spirometry is required to make a formal diagnosis of
COPD. Patients with partly or fully reversible airflow obstruction
may have fundamentally different pathological processes con-
tributing to airflow obstruction. One potential bias is that there
may be some cases with misclassification of either an asthma
diagnosis or the COPD diagnosis. In addition, both asthma and
COPD are common diagnoses and may coexist in the same
individuals. The associations with lung function that we show
were found in the general population and if the SNP effects
are specific to asthma and not present in COPD, then the in-
clusion of patients with asthma could overestimate the contri-
bution of the SNPs to COPD. However, we examined the effects
of exclusion of patients with known asthma from the case subjects
in a subset of the data with asthma diagnosis available and this
did not alter the findings substantially (Figure E2). In addition,
within the Nottingham Smokers Study, for which we have
in-depth phenotype data and know that individuals with asthma
and never-smokers with airflow obstruction have been specifically
excluded, we found similar effect estimates. The effect size esti-
mates in Nottingham Smokers were also consistent with effects
on COPD for our sentinel SNPs in HTR4, GSTCD, and TNS1
(Figure 3).
Various criteria have been proposed for the classification of
COPD. Our main analysis was based on GOLD criteria (17). As
misclassification is particularly likely to occur when there is
poor separation of criteria for case subjects and control subjects,
we excluded from our analyses altogether any individuals with
mild COPD (stage 1 GOLD criteria: FEV1/FVC , 70% but
FEV1 > 80% predicted).
Our conclusionswere notmaterially altered by classifying cases
instead on the basis of lower limit of normal equations (18) (Figure
E3). Misclassification could also occur as a consequence of spi-
rometry measurement error, and this too would tend to lead to
underestimation of the effects of the SNPs studied. An important
limitation of our study is that the misclassification and smoking
exposure cannot be fully addressed, using these cohorts, because
postbronchodilator spirometry and quantification of tobacco smoke
exposure is not captured in several of our cohorts. Further studies
of patients with COPDwith more detailed smoking exposure meas-
urements and more extensive respiratory phenotyping should pro-
vide further insight into the precise effects of these SNPs on COPD
risk and COPD progression.
We focused on the study of SNPs in six loci: TNS1, GSTCD,
HHIP, HTR4, AGER, and THSD4. Further studies will be re-
quired to investigate the potential association with COPD of
SNPs in the regions of GPR126, ADAM19, PTCH, and PID1
(additional regions described by the Cohorts for Heart and Ag-
ing Research in Genomic Epidemiology [CHARGE] Consor-
tium) (8). The addition of these SNPs, the sentinel SNP from
FAM13A (associated with COPD and lung function [8, 12]),
CHRNA3/5 (11), and other new loci from ongoing powerful
genome-wide association studies to the risk score we con-
structed would be expected to improve the discrimination of
such a score for prediction of COPD. With some exceptions,
such as the major histocompatibility region, genome-wide asso-
ciation studies have been successful in localizing association
signals (34, 35), but further research is likely to lead to im-
proved resolution of association signals and possibly to detec-
tion of multiple independent causal variants at each of these
loci. The simple risk score we present here would need to be
adapted to incorporate an appropriate weighting as the score
incorporates more SNPs, with a greater range of effect sizes.
However, for the limited number of SNPs we examined, the
inclusion of a weighting (based on the allelic effect size esti-
mate) did not materially alter our findings. We also constructed
risk scores in a subset of the data, measuring the effect on
COPD per risk allele in all individuals and in ever-smokers only;
the odds ratios were 1.14 and 1.13, respectively, suggesting that
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the effect of these loci on COPD is similar in the general pop-
ulation and in ever-smokers only. As more complete risk scores
are constructed, it will be important to investigate their predictive
potential in subgroups stratified by smoking status, and to examine
whether such a score can improve on risk prediction from conven-
tional risk factors alone (including age, sex, smoking status, history
of asthma, and family history, where available).
Our study demonstrates that some loci underlying lung func-
tion are associated with COPD, and provides a proof of concept
that investigation of genetic determinants of lung function can be
a successful strategy to discover molecular pathways underlying
COPD. Pathways involving HTR4, GSTCD, and TNS1 are
strong candidates for potential interventions to prevent or alle-
viate COPD. We show, in studies unaffected by winner’s curse
bias, that the highest risk category of a six-SNP risk score is
associated with a 1.6-fold risk of COPD compared with a com-
mon baseline group of seven risk alleles. It is not yet known
whether these SNPs could contribute to a clinically useful strat-
egy for prediction and intervention to prevent COPD, although
the high absolute risk of COPD in smokers would suggest that
the clinical and public health impact of such an approach is
worthy of investigation as more loci are discovered and incor-
porated into risk scores.
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